Wednesday, March 9, 2016
10:45 – 12:00pm
Immuno-Oncology II: Next Wave IO Targets and Modalities
- Jeffrey M. Bockman, PhD, Vice President, Defined Health.
- Kenneth Carter, PhD, President and Chief Executive Officer, NexImmune
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString Technologies
- Thomas Gajewski, MD, PhD, Professor of Medicine, University of Chicago
- Rachel W. Humphrey, MD, Chief Medical Officer, CytomX Therapeutics, Inc.
- Christopher Lengauer, PhD, MBA, Chief Scientific Officer, Blueprint Medicines
- Peter Sandor, MD, MBA, VP, Head of Oncology Therapeutic Area in Marketing Strategy, Astellas Pharma